×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Benign Prostatic Hyperplasia Treatment Market Share

ID: MRFR/HC/10317-HCR
128 Pages
Kinjoll Dey
October 2025

Benign Prostatic Hyperplasia Treatment Market Research Report Information By Therapeutic Class (Alpha Blockers, 5- Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others), By Therapy (Mono Drug Therapy and Combination Drug Therapy), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) – Market Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Benign Prostatic Hyperplasia Treatment Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Share

Benign Prostatic Hyperplasia Treatment Market Share Analysis

To get an upper hand, firms in the BPH Treatment market execute key situating procedures. Separation and item development are fundamental procedures. Organizations can separate themselves by allotting assets towards insignificantly intrusive systems, creative drugs, and high-level clinical gadgets. The arrangement of imaginative, client driven arrangements enhance the allure of their items to medical services experts and people looking for strong, insignificantly obtrusive solutions for BPH. By laying out essential organizations with medical services establishments and urologists, associations can further develop their portion of the overall industry situating, get close enough to a more extensive scope of patients, gain experiences into clinical necessities, make commitments to clinical exploration, and grandstand the viability of BPH therapies. Portion of the overall industry situating procedures intensely depend on customization and flexibility. Chasing meets the assorted socioeconomics of patients, organizations foster adaptable BPH medicines, which thus further develop market reception and responsiveness. Instruction and promoting uses are fundamental for piece of the pie situating. To draw in urologists and patients, organizations can improve their validity by underscoring the upsides of their BPH medicines, including side effect alleviation, upgraded personal satisfaction, and abbreviated recuperation periods. Associations should give priority to research, advancement, and clinical criticism to work on the exhibition, security, and adequacy of BPH medicines. This will ensure their capacity to stay serious on the lookout and actually answer changing clinical requests. Associations put an exceptional on persistent cordial connection points, consistent combination with medical services frameworks, and easy to understand plans to foster gadgets that upgrade the experience of patients and secure themselves as leaders in clinical arrangements that are thoughtful of their necessities. Long haul achievement and development of BPH treatment suppliers are dependent upon laying out certainty with medical care partners through vigorous pharmacovigilance frameworks, quality administration practices, and security concerns. Carrying out an essential methodology by laying out worldwide organizations and getting administrative endorsements to accomplish worldwide development is moderate. Associations that are adroit at exploring the intricacies of global administrative scenes, getting approvals in critical business sectors, and shaping unions with worldwide urology associations can fundamentally grow their market presence. Laying out a worldwide presence empowers associations to exploit different market open doors, satisfy explicit territorial requests, and reinforce their serious standing.

Author
Kinjoll Dey
Research Analyst Level I

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Get In Touch

Leave a Comment

FAQs

What is the current valuation of the Benign Prostatic Hyperplasia Treatment Market?

The market valuation was 12.45 USD Billion in 2024.

What is the projected market size for the Benign Prostatic Hyperplasia Treatment Market by 2035?

The market is projected to reach 22.44 USD Billion by 2035.

What is the expected CAGR for the Benign Prostatic Hyperplasia Treatment Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 5.5%.

Which therapeutic classes are leading in the Benign Prostatic Hyperplasia Treatment Market?

Alpha Blockers and 5-Alpha Reductase Inhibitors are leading therapeutic classes, with valuations of 6.73 and 4.52 USD Billion respectively by 2035.

What are the projected revenues for Mono Drug Therapy and Combination Drug Therapy by 2035?

Both Mono Drug Therapy and Combination Drug Therapy are projected to reach 11.22 USD Billion by 2035.

Who are the key players in the Benign Prostatic Hyperplasia Treatment Market?

Key players include Astellas Pharma, Boehringer Ingelheim, Eli Lilly and Company, and others.

Market Summary

As per MRFR analysis, the Benign Prostatic Hyperplasia Treatment Market was estimated at 12.45 USD Billion in 2024. The market is projected to grow from 13.13 USD Billion in 2025 to 22.44 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.5 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Benign Prostatic Hyperplasia Treatment Market is experiencing a transformative shift towards innovative and patient-centric solutions.

  • The market is witnessing a rise in minimally invasive techniques, enhancing patient recovery and satisfaction. North America remains the largest market, driven by advanced healthcare infrastructure and high treatment adoption rates. In the Asia-Pacific region, the market is growing rapidly, fueled by increasing awareness and healthcare access. Key market drivers include the aging population and advancements in treatment modalities, particularly in Alpha Blockers and Combination Drug Therapy segments.

Market Size & Forecast

2024 Market Size 12.45 (USD Billion)
2035 Market Size 22.44 (USD Billion)
CAGR (2025 - 2035) 5.5%
Largest Regional Market Share in 2024 North America

Major Players

<p>Astellas Pharma (JP), Boehringer Ingelheim (DE), Eli Lilly and Company (US), <a href="https://gskpro.com/en-xg/therapy-areas/urology/news-updates/updated_guidelines_for_the_management_and_treatment_of_patients_with_benign_prostatic_hyperplasia/">GlaxoSmithKline</a> (GB), Merck &amp; Co. (US), Pfizer Inc. (US), Sanofi (FR), Teva Pharmaceutical Industries (IL), AbbVie Inc. (US)</p>

Market Trends

The Benign Prostatic Hyperplasia Treatment Market is currently experiencing notable transformations driven by advancements in medical technology and an increasing awareness of prostate health. As the global population ages, the prevalence of benign prostatic hyperplasia (BPH) rises, prompting a surge in demand for effective treatment options. This market encompasses a variety of therapeutic approaches, including pharmacological treatments, minimally invasive procedures, and surgical interventions. The growing emphasis on patient-centered care is influencing the development of innovative therapies that prioritize safety and efficacy, thereby enhancing the overall treatment experience for individuals affected by BPH. Moreover, the landscape of the Benign Prostatic Hyperplasia Treatment Market is shaped by ongoing research and development efforts aimed at improving existing therapies and introducing novel solutions. Collaboration among pharmaceutical companies, healthcare providers, and research institutions appears to be fostering a dynamic environment conducive to innovation. Additionally, the integration of digital health technologies, such as telemedicine and mobile health applications, is likely to enhance patient engagement and adherence to treatment regimens. As the market evolves, stakeholders must remain attuned to emerging trends and shifts in patient preferences to effectively address the diverse needs of those living with benign prostatic hyperplasia.

Rise of Minimally Invasive Techniques

The trend towards minimally invasive techniques in the Benign Prostatic Hyperplasia Treatment Market is gaining traction. These methods, which include laser therapies and transurethral procedures, offer patients reduced recovery times and lower complication rates compared to traditional surgical options. As awareness of these benefits spreads, more patients are likely to opt for these alternatives, influencing market dynamics.

Increased Focus on Patient-Centric Solutions

There is a growing emphasis on patient-centric solutions within the Benign Prostatic Hyperplasia Treatment Market. Healthcare providers are increasingly prioritizing treatments that not only address the medical aspects of BPH but also consider the quality of life of patients. This shift is prompting the development of therapies that are tailored to individual needs, potentially leading to improved patient satisfaction and adherence.

Integration of Digital Health Technologies

The integration of digital health technologies is transforming the Benign Prostatic Hyperplasia Treatment Market. Telemedicine and mobile health applications are becoming essential tools for patient management, allowing for remote consultations and monitoring. This trend may enhance accessibility to care and facilitate better communication between patients and healthcare providers, ultimately improving treatment outcomes.

Benign Prostatic Hyperplasia Treatment Market Market Drivers

Rising Healthcare Expenditure

The increasing healthcare expenditure across various regions is significantly influencing the Benign Prostatic Hyperplasia Treatment Market. As governments and private sectors allocate more resources to healthcare, there is a corresponding rise in the availability of advanced treatment options for BPH. This trend is particularly evident in developed economies, where healthcare budgets are expanding to accommodate innovative therapies and technologies. The willingness of patients to invest in their health, coupled with insurance coverage for BPH treatments, is likely to enhance market growth. Consequently, the Benign Prostatic Hyperplasia Treatment Market stands to benefit from this upward trajectory in healthcare spending, as more individuals seek timely and effective interventions.

Advancements in Treatment Modalities

Innovations in treatment modalities are playing a crucial role in shaping the Benign Prostatic Hyperplasia Treatment Market. The introduction of new pharmacological agents, such as alpha-blockers and 5-alpha-reductase inhibitors, has expanded the therapeutic options available for patients. Additionally, minimally invasive procedures, including laser therapy and transurethral resection of the prostate, are gaining traction due to their effectiveness and reduced recovery times. The market is anticipated to benefit from ongoing research and development efforts aimed at enhancing treatment efficacy and patient outcomes. As these advancements continue to emerge, they are likely to attract more patients seeking effective solutions for BPH, thereby propelling the growth of the Benign Prostatic Hyperplasia Treatment Market.

Growing Awareness and Education Initiatives

The Benign Prostatic Hyperplasia Treatment Market is witnessing a surge in growth driven by increased awareness and education initiatives surrounding BPH. Healthcare organizations and advocacy groups are actively promoting information about the condition, its symptoms, and available treatment options. This heightened awareness is encouraging men to seek medical advice and treatment sooner, which is crucial for effective management of BPH. Educational campaigns are also addressing the stigma associated with prostate health, leading to a more open dialogue about the condition. As awareness continues to rise, it is expected that more patients will engage with healthcare providers, thereby contributing to the expansion of the Benign Prostatic Hyperplasia Treatment Market.

Aging Population and Rising Incidence of BPH

The Benign Prostatic Hyperplasia Treatment Market is experiencing growth due to the increasing prevalence of BPH among the aging population. As men age, the likelihood of developing BPH rises significantly, with studies indicating that nearly 50% of men aged 50 and older may experience symptoms. This demographic shift is expected to drive demand for effective treatment options, including medications and surgical interventions. The market is projected to expand as healthcare providers seek to address the needs of this growing patient population. Furthermore, the rising awareness of BPH and its impact on quality of life is likely to encourage more individuals to seek treatment, thereby contributing to the overall growth of the Benign Prostatic Hyperplasia Treatment Market.

Integration of Telemedicine in BPH Management

The integration of telemedicine into the management of BPH is emerging as a transformative factor in the Benign Prostatic Hyperplasia Treatment Market. Telehealth services are facilitating remote consultations, allowing patients to receive timely medical advice without the need for in-person visits. This is particularly beneficial for individuals in rural or underserved areas, where access to specialized care may be limited. The convenience and efficiency of telemedicine are likely to encourage more patients to seek treatment for BPH, thus expanding the market. As healthcare systems continue to embrace digital solutions, the Benign Prostatic Hyperplasia Treatment Market is poised for growth, driven by the increasing adoption of telehealth technologies.

Market Segment Insights

By Therapeutic Class: Alpha Blockers (Largest) vs. 5-Alpha Reductase Inhibitors (Fastest-Growing)

<p>In the Benign Prostatic Hyperplasia (BPH) treatment market, Alpha Blockers emerge as the largest segment, commanding a significant portion of the market share. These medications work by relaxing the muscles in the prostate and bladder neck, facilitating easier urination, which makes them a preferred choice among healthcare providers. Conversely, 5-Alpha Reductase Inhibitors, while currently smaller in market share relative to Alpha Blockers, are witnessing accelerated growth due to their effectiveness in reducing prostate size and long-term treatment benefits. This growth is further fueled by increased awareness and diagnosis of BPH among the aging population. The growth trends in the therapeutic class for BPH treatment are driven by several factors, including advancements in treatment efficacy and the widening acceptance of newer medications. As patients and healthcare providers seek more effective long-term solutions, the demand for 5-Alpha Reductase Inhibitors is expected to rise significantly. Moreover, ongoing research and developments in drug formulations are likely to enhance the utility of these therapeutics, thereby positioning them as a robust option in BPH management. Increased focus on patient outcomes and satisfaction will continue to dictate the success of this segment in the coming years.</p>

<p>Alpha Blockers (Dominant) vs. 5-Alpha Reductase Inhibitors (Emerging)</p>

<p>Alpha Blockers currently hold a dominant position in the Benign Prostatic Hyperplasia treatment landscape, characterized by a broad acceptance among both patients and healthcare providers. These medications provide rapid relief of urinary symptoms, appealing to patients seeking immediate improvements. In contrast, 5-Alpha Reductase Inhibitors are emerging as a vital segment due to their long-term impact on prostate size and symptoms. Their slower onset acts to differentiate them from Alpha Blockers, but the therapeutic effectiveness in managing BPH long-term is becoming increasingly recognized. Both segments offer unique benefits, with Alpha Blockers leading in immediate relief while 5-Alpha Reductase Inhibitors are gaining traction for their sustained therapeutic benefits.</p>

By Therapy: Mono Drug Therapy (Largest) vs. Combination Drug Therapy (Fastest-Growing)

<p>In the Benign Prostatic Hyperplasia (BPH) Treatment Market, Mono Drug Therapy stands out as the largest segment, capturing a significant share of the market. This approach, utilizing single-agent drugs, has been a traditional choice among healthcare providers, thereby establishing a strong foothold. The efficacy and simplicity of mono therapies contribute to their ongoing popularity, particularly for patients with mild to moderate BPH symptoms. On the other hand, Combination Drug Therapy is emerging as the fastest-growing segment within this market. The combination of different therapeutic agents allows for enhanced efficacy, particularly in more severe cases of BPH. As patient preferences shift towards personalized medicine, the demand for combination therapies is on the rise. Increased awareness of treatment options and the push for holistic patient care are significant drivers of this growth trend.</p>

<p>Therapy: Mono Drug (Dominant) vs. Combination Drug (Emerging)</p>

<p>Mono Drug Therapy is characterized by its straightforward approach, employing a single medication to alleviate the symptoms of BPH. This method is favored for its simplicity and controlled dosing, making it a reliable option for a substantial number of patients. Its dominance in the market is largely attributed to established treatments and a solid understanding of their mechanisms. However, Combination Drug Therapy is emerging strongly by addressing a broader range of symptoms more effectively than monotreatment. This segment combines multiple agents to tackle the complexity of BPH, thereby appealing to patients with varying severity levels and coexisting conditions. As clinicians seek to optimize therapeutic outcomes, this segment's tailored approach is expected to garner increasing acceptance, positioning it as a noteworthy competitor to mono therapies.</p>

Get more detailed insights about Benign Prostatic Hyperplasia Treatment Market Research Report—Global Forecast till 2035

Regional Insights

North America : Leading Market for Treatments

North America is the largest market for Benign Prostatic Hyperplasia (BPH) treatments, accounting for approximately 45% of the global market share. The region's growth is driven by an aging population, increasing prevalence of BPH, and advancements in treatment options. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring the availability of innovative therapies and medications. The United States is the primary contributor to this market, with significant investments from key players such as Pfizer Inc., Merck & Co., and AbbVie Inc. The competitive landscape is characterized by a mix of established pharmaceutical companies and emerging biotech firms, all striving to capture market share through innovative solutions and effective marketing strategies. The presence of robust healthcare infrastructure also supports the growth of BPH treatments in this region.

Europe : Regulatory Support and Innovation

Europe is the second-largest market for Benign Prostatic Hyperplasia treatments, holding around 30% of the global market share. The region's growth is fueled by increasing awareness of BPH, a rising geriatric population, and favorable regulatory frameworks that encourage the development of new therapies. The European Medicines Agency (EMA) plays a crucial role in ensuring the safety and efficacy of treatments, which boosts consumer confidence and market demand. Leading countries in this market include Germany, France, and the UK, where healthcare systems are increasingly adopting advanced treatment options. Major players like Astellas Pharma and Boehringer Ingelheim are actively involved in research and development, contributing to a competitive landscape that fosters innovation. The presence of well-established healthcare networks further enhances the accessibility of BPH treatments across Europe.

Asia-Pacific : Emerging Market Potential

The Asia-Pacific region is witnessing significant growth in the Benign Prostatic Hyperplasia treatment market, accounting for approximately 15% of the global share. Factors such as increasing urbanization, rising healthcare expenditure, and a growing awareness of prostate health are driving demand. Additionally, government initiatives aimed at improving healthcare access and affordability are expected to further boost market growth in the coming years. Countries like Japan, China, and India are leading the charge in this market, with a mix of local and international players vying for market share. Companies such as Eli Lilly and Teva Pharmaceutical Industries are focusing on expanding their presence through strategic partnerships and innovative product offerings. The competitive landscape is evolving, with an increasing number of generic medications entering the market, providing more options for patients.

Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region represents an emerging market for Benign Prostatic Hyperplasia treatments, holding about 10% of the global market share. The growth in this region is driven by increasing awareness of prostate health, rising healthcare investments, and a growing population of elderly men. However, challenges such as limited access to healthcare facilities and varying regulatory environments can hinder market expansion. Countries like South Africa and the UAE are at the forefront of this market, with increasing healthcare initiatives aimed at improving access to treatments. Key players, including GlaxoSmithKline and Sanofi, are exploring opportunities to expand their footprint in this region. The competitive landscape is characterized by a mix of multinational corporations and local firms, all striving to meet the growing demand for effective BPH treatments.

Key Players and Competitive Insights

The Benign Prostatic Hyperplasia (BPH) Treatment Market is characterized by a dynamic competitive landscape, driven by an increasing prevalence of BPH among aging populations and a growing demand for effective therapeutic options. Key players such as Astellas Pharma (Japan), Merck & Co. (US), and AbbVie Inc. (US) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Astellas Pharma (Japan) focuses on developing novel therapies, while Merck & Co. (US) emphasizes expanding its product portfolio through strategic acquisitions. AbbVie Inc. (US) is actively pursuing collaborations to enhance its research capabilities, thereby shaping a competitive environment that prioritizes innovation and strategic alliances.

The market structure appears moderately fragmented, with several players vying for market share. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. This trend is indicative of a broader strategy among key players to respond to regional demands and regulatory requirements, thereby solidifying their competitive positions. The collective influence of these companies fosters a competitive atmosphere where innovation and operational excellence are paramount.

In August 2025, Astellas Pharma (Japan) announced the initiation of a Phase III clinical trial for its new BPH treatment, which aims to provide a more effective solution for patients. This strategic move underscores Astellas' commitment to innovation and its focus on addressing unmet medical needs in the BPH treatment landscape. The trial's outcomes could significantly impact the company's market positioning and contribute to its long-term growth strategy.

In September 2025, Merck & Co. (US) completed the acquisition of a biotechnology firm specializing in urology, which is expected to enhance its BPH treatment portfolio. This acquisition reflects Merck's strategy to bolster its research and development capabilities, allowing for the introduction of cutting-edge therapies. The integration of new technologies and expertise could potentially accelerate the development of innovative solutions for BPH, thereby strengthening Merck's competitive edge.

In July 2025, AbbVie Inc. (US) entered into a strategic partnership with a leading digital health company to develop a telehealth platform aimed at improving patient access to BPH treatments. This initiative highlights AbbVie's focus on digital transformation and patient-centric care, which are increasingly vital in today's healthcare landscape. By leveraging technology, AbbVie aims to enhance patient engagement and streamline treatment pathways, positioning itself favorably in a competitive market.

As of October 2025, the BPH treatment market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence in therapeutic development. Strategic alliances are becoming increasingly important, as companies seek to combine resources and expertise to drive innovation. The competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative treatment options, and reliable supply chains. This shift suggests that companies prioritizing research and development, alongside strategic partnerships, will be better positioned to thrive in the evolving landscape.

Key Companies in the Benign Prostatic Hyperplasia Treatment Market market include

Industry Developments

October 2020 A merger between Astellas Pharma Inc. and Takeda Pharmaceutical Company Limited was announced; it is anticipated to close in 2023. The goal of this merger is to establish a global leader in the creation and marketing of cutting-edge therapies for people with benign prostatic hyperplasia (BPH).

Future Outlook

Benign Prostatic Hyperplasia Treatment Market Future Outlook

<p>The Benign Prostatic Hyperplasia Treatment Market is projected to grow at a 5.5% CAGR from 2024 to 2035, driven by increasing prevalence and advancements in treatment options.</p>

New opportunities lie in:

  • <p>Development of telehealth platforms for remote patient monitoring</p><p>Investment in minimally invasive surgical technologies</p><p>Expansion of personalized medicine approaches for treatment optimization</p>

<p>By 2035, the market is expected to be robust, reflecting significant advancements and increased patient access.</p>

Market Segmentation

Benign Prostatic Hyperplasia Treatment Market Therapy Outlook

  • Mono Drug Therapy
  • Combination Drug Therapy

Benign Prostatic Hyperplasia Treatment Market Therapeutic Class Outlook

  • Alpha Blockers
  • 5- Alpha Reductase Inhibitors
  • Phosphodiesterase-5 Inhibitors
  • Others

Report Scope

MARKET SIZE 202412.45(USD Billion)
MARKET SIZE 202513.13(USD Billion)
MARKET SIZE 203522.44(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)5.5% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Billion
Key Companies ProfiledMarket analysis in progress
Segments CoveredMarket segmentation analysis in progress
Key Market OpportunitiesEmergence of minimally invasive therapies enhances patient compliance in the Benign Prostatic Hyperplasia Treatment Market.
Key Market DynamicsRising demand for minimally invasive procedures drives innovation in Benign Prostatic Hyperplasia treatment options and technologies.
Countries CoveredNorth America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Benign Prostatic Hyperplasia Treatment Market?

The market valuation was 12.45 USD Billion in 2024.

What is the projected market size for the Benign Prostatic Hyperplasia Treatment Market by 2035?

The market is projected to reach 22.44 USD Billion by 2035.

What is the expected CAGR for the Benign Prostatic Hyperplasia Treatment Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 5.5%.

Which therapeutic classes are leading in the Benign Prostatic Hyperplasia Treatment Market?

Alpha Blockers and 5-Alpha Reductase Inhibitors are leading therapeutic classes, with valuations of 6.73 and 4.52 USD Billion respectively by 2035.

What are the projected revenues for Mono Drug Therapy and Combination Drug Therapy by 2035?

Both Mono Drug Therapy and Combination Drug Therapy are projected to reach 11.22 USD Billion by 2035.

Who are the key players in the Benign Prostatic Hyperplasia Treatment Market?

Key players include Astellas Pharma, Boehringer Ingelheim, Eli Lilly and Company, and others.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. EXECUTIVE SUMMARY
      1. Market Overview
      2. Key Findings
      3. Market Segmentation
      4. Competitive Landscape
      5. Challenges and Opportunities
      6. Future Outlook 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    2. MARKET INTRODUCTION
      1. Definition
      2. Scope of the study
    3. RESEARCH METHODOLOGY
      1. Overview
      2. Data Mining
      3. Secondary Research
      4. Primary Research
      5. Forecasting Model
      6. Market Size Estimation
      7. Data Triangulation
      8. Validation 3 SECTION III: QUALITATIVE ANALYSIS
    4. MARKET DYNAMICS
      1. Overview
      2. Drivers
      3. Restraints
      4. Opportunities
    5. MARKET FACTOR ANALYSIS
      1. Value chain Analysis
      2. Porter's Five Forces Analysis
      3. COVID-19 Impact Analysis
    6. Healthcare, BY Therapeutic Class (USD Billion)
      1. Alpha Blockers
      2. 5- Alpha Reductase Inhibitors
      3. Phosphodiesterase-5 Inhibitors
      4. Others
    7. Healthcare, BY Therapy (USD Billion)
      1. Mono Drug Therapy
      2. Combination Drug Therapy
    8. Healthcare, BY Region (USD Billion)
      1. North America
      2. Europe
      3. APAC
      4. South America
      5. MEA
    9. Competitive Landscape
      1. Overview
      2. Competitive Analysis
      3. Market share Analysis
      4. Major Growth Strategy in the Healthcare
      5. Competitive Benchmarking
      6. Leading Players in Terms of Number of Developments in the Healthcare
      7. Key developments and growth strategies
      8. Major Players Financial Matrix
    10. Company Profiles
      1. Astellas Pharma (JP)
      2. Boehringer Ingelheim (DE)
      3. Eli Lilly and Company (US)
      4. GlaxoSmithKline (GB)
      5. Merck & Co. (US)
      6. Pfizer Inc. (US)
      7. Sanofi (FR)
      8. Teva Pharmaceutical Industries (IL)
      9. AbbVie Inc. (US)
    11. Appendix
      1. References
      2. Related Reports 6 LIST OF FIGURES
    12. MARKET SYNOPSIS
    13. NORTH AMERICA MARKET ANALYSIS
    14. US MARKET ANALYSIS BY THERAPEUTIC CLASS
    15. US MARKET ANALYSIS BY THERAPY
    16. CANADA MARKET ANALYSIS BY THERAPEUTIC CLASS
    17. CANADA MARKET ANALYSIS BY THERAPY
    18. EUROPE MARKET ANALYSIS
    19. GERMANY MARKET ANALYSIS BY THERAPEUTIC CLASS
    20. GERMANY MARKET ANALYSIS BY THERAPY
    21. UK MARKET ANALYSIS BY THERAPEUTIC CLASS
    22. UK MARKET ANALYSIS BY THERAPY
    23. FRANCE MARKET ANALYSIS BY THERAPEUTIC CLASS
    24. FRANCE MARKET ANALYSIS BY THERAPY
    25. RUSSIA MARKET ANALYSIS BY THERAPEUTIC CLASS
    26. RUSSIA MARKET ANALYSIS BY THERAPY
    27. ITALY MARKET ANALYSIS BY THERAPEUTIC CLASS
    28. ITALY MARKET ANALYSIS BY THERAPY
    29. SPAIN MARKET ANALYSIS BY THERAPEUTIC CLASS
    30. SPAIN MARKET ANALYSIS BY THERAPY
    31. REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC CLASS
    32. REST OF EUROPE MARKET ANALYSIS BY THERAPY
    33. APAC MARKET ANALYSIS
    34. CHINA MARKET ANALYSIS BY THERAPEUTIC CLASS
    35. CHINA MARKET ANALYSIS BY THERAPY
    36. INDIA MARKET ANALYSIS BY THERAPEUTIC CLASS
    37. INDIA MARKET ANALYSIS BY THERAPY
    38. JAPAN MARKET ANALYSIS BY THERAPEUTIC CLASS
    39. JAPAN MARKET ANALYSIS BY THERAPY
    40. SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC CLASS
    41. SOUTH KOREA MARKET ANALYSIS BY THERAPY
    42. MALAYSIA MARKET ANALYSIS BY THERAPEUTIC CLASS
    43. MALAYSIA MARKET ANALYSIS BY THERAPY
    44. THAILAND MARKET ANALYSIS BY THERAPEUTIC CLASS
    45. THAILAND MARKET ANALYSIS BY THERAPY
    46. INDONESIA MARKET ANALYSIS BY THERAPEUTIC CLASS
    47. INDONESIA MARKET ANALYSIS BY THERAPY
    48. REST OF APAC MARKET ANALYSIS BY THERAPEUTIC CLASS
    49. REST OF APAC MARKET ANALYSIS BY THERAPY
    50. SOUTH AMERICA MARKET ANALYSIS
    51. BRAZIL MARKET ANALYSIS BY THERAPEUTIC CLASS
    52. BRAZIL MARKET ANALYSIS BY THERAPY
    53. MEXICO MARKET ANALYSIS BY THERAPEUTIC CLASS
    54. MEXICO MARKET ANALYSIS BY THERAPY
    55. ARGENTINA MARKET ANALYSIS BY THERAPEUTIC CLASS
    56. ARGENTINA MARKET ANALYSIS BY THERAPY
    57. REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC CLASS
    58. REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPY
    59. MEA MARKET ANALYSIS
    60. GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC CLASS
    61. GCC COUNTRIES MARKET ANALYSIS BY THERAPY
    62. SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC CLASS
    63. SOUTH AFRICA MARKET ANALYSIS BY THERAPY
    64. REST OF MEA MARKET ANALYSIS BY THERAPEUTIC CLASS
    65. REST OF MEA MARKET ANALYSIS BY THERAPY
    66. KEY BUYING CRITERIA OF HEALTHCARE
    67. RESEARCH PROCESS OF MRFR
    68. DRO ANALYSIS OF HEALTHCARE
    69. DRIVERS IMPACT ANALYSIS: HEALTHCARE
    70. RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    71. SUPPLY / VALUE CHAIN: HEALTHCARE
    72. HEALTHCARE, BY THERAPEUTIC CLASS, 2024 (% SHARE)
    73. HEALTHCARE, BY THERAPEUTIC CLASS, 2024 TO 2035 (USD Billion)
    74. HEALTHCARE, BY THERAPY, 2024 (% SHARE)
    75. HEALTHCARE, BY THERAPY, 2024 TO 2035 (USD Billion)
    76. BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES
    77. LIST OF ASSUMPTIONS
    78. North America MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    79. US MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    80. Canada MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    81. Europe MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    82. Germany MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    83. UK MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    84. France MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    85. Russia MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    86. Italy MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    87. Spain MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    88. Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    89. APAC MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    90. China MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    91. India MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    92. Japan MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    93. South Korea MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    94. Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    95. Thailand MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    96. Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    97. Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    98. South America MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    99. Brazil MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    100. Mexico MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    101. Argentina MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    102. Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    103. MEA MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    104. GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    105. South Africa MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    106. Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      2. BY THERAPY, 2025-2035 (USD Billion)
    107. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    108. ACQUISITION/PARTNERSHIP

Benign Prostatic Hyperplasia Treatment aMarket Segmentation

Benign Prostatic Hyperplasia Treatment Therapeutics Class Outlook (USD Billion, 2018-2032)

Alpha blockersa

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment Therapy Outlook (USD Billion, 2018-2032)

Mono drug therapy

Combination drug therapy

Benign Prostatic Hyperplasia Treatment Regional Outlook (USD Billion, 2018-2032)

North America Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

US Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

Canada Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

Europe Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

Germany Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

France Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

UK Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

Italy Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

Spain Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

Rest Of Europe Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

Asia-Pacific Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

China Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

Japan Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

India Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

Australia Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

Rest of the World Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

Middle East Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

Africa Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

Latin America Outlook (USD Billion, 2018-2032)

Benign Prostatic Hyperplasia Treatment by Therapeutics Class

Alpha blockers

5- alpha reductase inhibitors

Phosphodiesterase-5 inhibitors

Others

Benign Prostatic Hyperplasia Treatment by Therapy

Mono drug therapy

Combination drug therapy

 

Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne

Founder
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓